The Form 144 signals intent to sell a modest position relative to market cap. Monitor for actual Form 4 filings to confirm execution and watch for any additional insider sales or changes in company guidance that might explain the timing.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $4.27entry
- T+1 · 3mo ago −1.99%α −1.32% · $4.18
- T+5 · 3mo ago −3.87%α −2.68% · $4.10
- T+20 · 2mo ago −19.58%α −18.05% · $3.43
- T+60 · 7d ago −26.14%α −23.38% · $3.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell approximately 82,563 shares of common stock with an estimated aggregate market value of ~$1.9 million. The shares were acquired through restricted stock and performance share grants between 2024 and 2025. This is a relatively small sale relative to C4's $502M market cap, but the insider's role and the timing (no specific catalyst noted) warrant monitoring for potential follow-through sales or insider sentiment shifts.
Key Facts
- Jay L. Geldmacher filed Form 144 to sell up to 82,563 shares of C4 Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is approximately $1,899,926.
- Shares were acquired via restricted stock and performance share grants dated 02/09/2025, 02/14/2025, 02/15/2025, 02/18/2024, and 02/14/2024.
- The filing date is August 14, 2026, with the proposed sale date also listed as August 14, 2026.
- The sale is planned through Morgan Stanley Smith Barney LLC Executive Financial Services.
Financial Impact
Proposed sale of ~82,563 shares valued at ~$1.9M, representing approximately 0.38% of C4's $502M market cap.
Risk Factors
- Insider sale may signal lack of confidence or personal liquidity needs; actual sale could pressure stock if executed in size.
- No specific catalyst identified; sale could be routine portfolio diversification.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-008190 |
| Document: 0001950047-26-008190-index.html | 0001950047-26-008190 |
| Document: 0001950047-26-008190.txt | 0001950047-26-008190 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Viewing Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers